Dr Jonathan Berg is a Senior Lecturer and Honorary Consultant in Clinical Genetics. He graduated in Medicine from the University of Edinburgh in 1989, and pursued specialist training in Clinical Genetics, including an MSc at the University of Newcastle upon Tyne in 1991, MRCP in Paediatrics in 1993, and MD awarded with distinction from the University of Edinburgh in 1998. He was a research fellow at Duke University from 1995 to 1996, and a research fellow and specialist registrar in Edinburgh between 1996 and 2000. In 2000, Dr Berg was appointed as a Senior Lecturer and Honorary Consultant at Guys Hospital and Kings College London. He moved to his current position in Dundee in June 2003.
As a Consultant, Dr Berg is responsible for Clinical Genetics services for Perthshire and also Antenatal genetics across Tayside. He has a clinical interest in hereditary vascular dysplasias, with a quarterly specialist clinic for this in Dundee.
Dr Berg is a member of the Scottish Specialty Training Committee for Clinical Genetics, representing Clinical Academic Training. He leads the Scottish Genetics Research Network and represents Scotland on the UK Clinical Research Network for Genetics.
In parallel with his teaching activities, Dr Berg pursues research into the genetic risk factors of breast cancer, investigating the clinical utility of low penetrance risk polymorphisms. This takes place in collaboration with the Tayside Tissue Bank and Departments of Surgery, Radiology and Pathology. A part of this work has been funded by the European union FP7 programme with collaborators in University College London, Nijmegen, Bremen and Berlin. Dr Berg also has ongoing research collaborations that link Genetic Core services to other research areas in the University, including work on pharmacogenetics in Attention Deficit Hyperactivity Disorder.
Dr Berg is responsible for the Undergraduate Genetics Curriculum in Dundee, which involves teaching in all 5 years of the course. He is also interested in developing clinical academic careers for doctors. Since 2006 he has co-organised the BMSc in Human Genetics and experimental Medicine in Dundee. He also supervises a number of post-graduate students undertaking the degree of Master of Science by Research.
Irving M, Elmslie F and Berg J (2002) The Genetics of Breast Cancer. International Journal of Clinical Practice. 56(9):677-682
Porteous M and Berg J (2004) Hereditary Haemorrhagic Telangiectasia. Management of Genetic Syndromes, 2nd Edition. Wiley.
Jonathan Berg and Sarju Mehta. Clinical Genetics. Chapter 3. Muirs Patholgy, Hodder Arnold 14th ed. 2008. Editors Reid, Harrison, Burt, Flemming and Harrison.
Jonathan Berg, Sudha Srinivasan and Doug Marchuk. ENG, ALK-1, and Smad 4 in Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Syndrome). Chapter 35. Inborn Errors of Development. Oxford University Press 2nd ed. 2008. Editors Epstein, Erickson and Wynshaw-Boris.
Peer Reviewed Publications (past 6 years)
Turnbull C, Seal S, Renwick A, Warren-Perry M, Hughes D, Elliott A, Pernet D, Peock S, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L; Breast Cancer Susceptibility Collaboration (UK), EMBRACE, Ahmed M, Eccles D, Evans DG, Donnelly P, Easton DF, Stratton MR, Rahman N. Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet. 2012;21:958-62.PMID:22072393
Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L; Breast Cancer Susceptibility Collaboration (UK), Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43:879-82. PMID:21822267
Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR, Purdie CA, Thompson AM, Jordan LB, Berg JN. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes. 2011;4:72.
Hall C, Cunningham J, Hislop R and Berg J. A boy with supernumerary mosaic trisomy 19q, involving 19q13.11 to 19q13.2, with macrocephaly, obesity and mild facial dysmorphism. Clin Dysmorphol. 2010;19(4):218-21
Zieba A, Wählby C, Hjelm F, Jordan L, Berg J, Landegren U, Pardali K. Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection. Clin Chem. 2010;56(1):99-110
Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, Enjolras O, Baselga E, Berg J, Dompmartin A, Ivarsson SA, Kangesu L, Lacassie Y, Murphy J, Teebi AS, Penington A, Rieu P, Vikkula M. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet. 2010;18(4):414-20
Anderson E, Berg J, Black R, Bradshaw N, Campbell J, Cetnarskyj R, Drummond S, Davidson R, Dunlop J, Fordyce A, Gibbons B, Goudie D, Gregory H, Hanning K, Holloway S, Longmuir M, McLeish L, Murday V, Miedzybrodska Z, Nicholson D, Pearson P, Porteous M, Reis M, Slater S, Smith K, Smyth E, Snadden L, Steel M, Stirling D, Watt C, Whyte C, Young D.Predicting breast cancer risk: implications of a "weak" family history. Fam Cancer. 2008;7(4):361-6.
Anderson E, Berg J, Black R, Bradshaw N, Campbell J, Carnaghan H, Cetnarkyj R, Drummond S, Davidson R, Dunlop J, Fordyce A, Gibbons B, Goudie D, Gregory H, Holloway S, Longmuir M, McLeish L, Murday V, Miedzybrodska Z, Nicholson D, Pearson P, Porteous M, Reis M, Slater S, Smith K, Smyth E, Snadden L, Steel M, Stirling D, Watt C, Whyte C, Young D. Prospective surveillance of women with a family history of breast cancer: auditing the risk threshold. Br J Cancer. 2008;98(4):840-4.
Holloway SM, Wilcox DE, Wilcox A, Dean JC, Berg JN, Goudie DR, Denvir MA, Porteous ME. Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland. Heart. 2008;94:633-6.Epub Oct.2007.
Deguara J, Burnand KG, Berg J, Green P, Lewis CM, Chinien G, Waltham M, Taylor P, Stern RF, Solomon E, Smith A. An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Hum Mol Genet. 2007;16(24):3002-7.
Barwell, J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris J R, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeles R, Hodgson S V. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. 2007;121(7):1631-6.
Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, Ball J, Barwell J, Gilchrist R, Pangon L, Berg J, Hodgson S. Is chromosome radiosensitivity and apoptotic response to irradiation correlated with cancer susceptibility? Int J Radiat Biol. 2007;83(1):1-12
Beger B, Robertson K, Evans A, Grant A, Berg J. Expression of endoglin and the activin receptor-like kinase 1 in skin suggests a role for these receptors in normal skin function and skin tumorigenesis. Br J Dermatol. 2006;154(2):379-82